• By ICR Secretariat
  • Posted Thursday, August 26, 2021

ESC 2021: Lexicon aims to make its heart failure case with sotagliflozin, a dual SGLT1 and SGLT2 inhibitor

https://www.fiercepharma.com/pharma/esc-2021-lexicon-aims-to-make-its-heart-failure-case-sotagliflozin-a-dual-sglt1-and-sglt2

While much of the attention at the European Society of Cardiology (ESC) is expected to center on forthcoming heart failure data for Eli Lilly and Boehringer Ingelheim’s Jardiance, Lexicon Pharmaceuticals thinks it has a winner in the dual SGLT1 and SGLT2 inhibitor sotagliflozin.